GP Ⅱb/Ⅲa受体拮抗剂在急性冠状动脉综合征经皮介入治疗中的应用被引量：5

下载PDF

导出

摘要急性冠状动脉综合征（acute coronary syndrome，ACS）包括急性心肌梗死和不稳定心绞痛，经皮冠状动脉介入治疗（percutaneous coronary intervetion，PCI）是治疗ACS的最有效、最常用的方法之一。有报道称，早期PCI可明显改善患者6个月及12个月的预后，但ACS发病过程及行PCI的术中、术后都有冠状动脉内皮的破坏，容易发生附壁血栓或血栓，以至导致冠状动脉血管栓塞以至心肌梗死。

作者尹晴马亚平聂涛屠伟峰

机构地区广州军区广州总医院麻醉科深圳瀚宇药业股份有限公司

出处《重庆医学》 CAS CSCD 北大核心 2013年第34期4206-4208,共3页 Chongqing medicine

基金国家高技术研究发展计划863计划项目(2011ZX092011-006)

关键词急性冠状动脉综合征血小板糖蛋白GPⅡb Ⅲa复合物拮抗剂和抑制剂治疗应用

分类号 R541.4 [医药卫生—心血管疾病]

引文网络
相关文献

参考文献21

1Dery JP, Campbell ME, Mathias J, et al. Complementaryeffects of thienopyridine pretreatment and platelet glyco-protein II b/ HI a integrin blockade with eptifibatide in cor-onary stent intervention; results from the ESPRIT trial[J]. Catheter Cardiovasc Interv,2007 ,70(1) :43-50. 被引量：1
2Langer HF, Gawaz M. Platelet-vessel wall interactions inatherosclerotic disease [J]. Thromb Haemost,2008,99(3):480-486. 被引量：1
3Altay H,Pehlivanoglu S. Editorial: Management of acutecoronary syndromes in patients presenting without persis-tent ST-segment elevation: What has changed in the newEuropean Society of Cardiology guideline? [J]. TurkKardiyol Dern Ars,2012,40(1) : 1-8. 被引量：1
4ESC guidelines for the management of acute coronary syn-dromes in patients presenting without persistent ST-segmentelevation. The Task Force for the management of acute coro-nary syndromes (ACS) in patients presenting without persis-tent ST-segment elevation of the European Society of Cardi-ology (ESC)[J]. G Ital Cardiol (Rome),2012,13 (3): 171-228. 被引量：1
5Grupo de Traboijo de SEC para Guia ESC 2011 de SCAS-EST,Fernandez_Ortiz A,Pan M, et al. Comments on theESC guidelines .for the management of acute coronarysyndromes in patients presenting without persistent ST-segment elevation. A report of the task force of the clini-cal practice guidelines committee of the Spanish Society ofCardiology[J]. Rev Esp Cardiol(Eng/Eol), 2012, 65 (2):125-130. 被引量：1
6Hamm CW,Bassand JP Agewall S,et al. ESC Guidelinesfor the management of acute coronary syndromes in pa-tients presenting without persistent ST-segment eleva-tion: The Task Force for the management of acute coro-nary syndromes (ACS) in patients presenting withoutpersistent ST-segment elevation of the European Societyof Cardiology ( ESC) [ J]. Eur Heart J,2011,32 ( 23 ):2999-3054. 被引量：1
7Muller C. New ESC guidelines for the management of a-cute coronary syndromes in patients presenting withoutpersistent ST'segment elevation [J]. Swiss Med Wkly?2012,142:wl3514. 被引量：1
8Schneider DJ. Anti-platelet therapy : glycoprotein H b-IIIaantagonists[J]. Br J Clin Pharmacol, 2011, 72 ( 4 ) : 672-682. 被引量：1
9Morel O,Morel N,Freyssinet JM,et al. Platelet micropar-ticles and vascular cells interactions : a checkpoint betweenthe haemostatic and thrombotic responses[Jj. Platelets,2008,19(l):9-23. 被引量：1
10Pannu RAndraws R. Effects of glycoprotein U b/HIa in-hibitors in patients undergoing percutaneous coronary in-tervention after pretreatment with clopidogrel: a meta-a-nalysis of randomized trials[J]. Crit Pathw Cardiol,2008,7(1):5-10. 被引量：1